Zack Snyder Takes A Swipe At Marvel And Ant-Man

Ben Arnold
image

‘Batman V Superman’ director Zack Snyder has dropped a few catty remarks aimed at rival comic book movie studio Marvel.

The DC movie helmsman singled out 'Ant-Man’ for his criticism, one of the least successful superhero movies for Marvel thus far.

- Guardians of the Galaxy 2 Title Revealed
- Channing Tatum Learns Card Tricks For Gambit
- Guardians of the Galaxy 2 Will Be More Emotional

Speaking to the Daily Beast, he was asked about Steven Spielberg’s recent remarks, in which the movie legend said 'there will be a time when the superhero movie goes the way of the Western’.

Snyder said: “I feel like he’s right. But I feel like Batman and Superman are transcendent of superhero movies in a way, because they’re Batman and Superman.

image

“They’re not just, like, the flavour of the week Ant-Man — not to be mean, but whatever it is. What is the next Blank-Man?”

Admittedly, Ant-Man, which starred Paul Rudd as the diminutive hero, didn’t do amazing business for Marvel.

Not widely known outside the comic book community, it brought in $384.8 million (£250 million) on a $130 million (£84 million) budget, meaning that after promotion and marketing, it can’t have been a great money spinner for the studio.

There was also turmoil in its production, when Marvel jettisoned original director and writer Edgar Wright after a protracted period of development.

But thus far the rivalry between DC Comics and Marvel in the movie business has been pretty cordial.

Maybe that’s set to change.

image

Snyder, who’s also directed comic book properties like '300’, Alan Moore’s classic 'Watchmen’, and 'Man of Steel’, will also helm the forthcoming 'Justice League’ movie, which will take on Marvel’s 'Avengers’ franchise pretty much head on.

'Batman V Superman: Dawn of Justice’ starring Ben Affleck, Henry Cavill and Jesse Eisenberg, is due out March 25 next year.

Image credits: Getty/Disney/Warner Bros

  • Up next
  • Up next
  • Up next
  • Up next

Latest Stories

  • Metso Corp's Dividend Analysis

    Metso Corp(OUKPY) recently announced a dividend of $0.1 per share, payable on 2024-05-22, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Metso Corp's dividend performance and assess its sustainability.

  • Alfa Laval AB's Dividend Analysis

    Alfa Laval AB (ALFVY) recently announced a dividend of $0.71 per share, payable on 2024-05-20, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Alfa Laval AB's dividend performance and assess its sustainability.

  • Supercar maker McLaren hit by £375m impairment charge

    McLaren Group, the British supercar maker and Formula One team-backer, has given lenders signs of an improvement in its financial performance even after a £375m impairment charge propelled it to a record loss last year. Sky News has learnt that McLaren has told bondholders that it made losses of £873m in the 12 months ending December 31. The Woking-based company's financial travails reflected an ongoing financial restructuring that was completed earlier this year.

  • Celanese Corp's Dividend Analysis

    Celanese Corp(NYSE:CE) recently announced a dividend of $0.7 per share, payable on 2024-05-13, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Celanese Corps dividend performance and assess its sustainability.

  • Q1 2024 Quantumscape Corp Earnings Call

    Q1 2024 Quantumscape Corp Earnings Call

  • Senate Passes $95 Billion Foreign Aid Package

    On April 23, the U.S. Senate voted 79-18 to approve foreign aid for Ukraine, Israel and Taiwan, 'The Guardian' reports. "Today the Senate sends a unified message to the entire world: America will always defend democracy in its hour of need.", Senate Majority Leader Chuck Schumer, via statement.

  • Comcast tops revenue estimates on streaming growth, strong park attendance

    Peacock added 3 million subscribers in the first quarter, taking its total to 34 million and outpacing estimates of 2.32 million by Visible Alpha, thanks to higher investments that Comcast hopes will help it compete better with Netflix and Disney+. Peacock became the first streaming service to exclusively air an NFL playoff game in January, which was one of its biggest growth drivers in the quarter.

  • UCB SA's Dividend Analysis

    UCB SA (UCBJY) recently announced a dividend of $0.73 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into UCB SA's dividend performance and assess its sustainability.

  • Sampo Oyj's Dividend Analysis

    Sampo Oyj (SAXPY) recently announced a dividend of $0.97 per share, payable on 2024-05-22, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Sampo Oyj's dividend performance and assess its sustainability.

  • UPDATE 1-Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

    Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda. The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.

  • Nasdaq's revenue beats on strong demand for fintech products

    Revenue from its financial technology unit surged 71% to $392 million in the first quarter, while revenue from its index business jumped 53% to $168 million. Nasdaq, like its peers, has been on an acquisition spree to diversify its portfolio of technology and intellectual property after regulations in 2005 opened the equities trading market up to competition from brokers. Net revenue in the first quarter jumped 22% to $1.12 billion.

  • Q1 2024 Moelis & Co Earnings Call

    Q1 2024 Moelis & Co Earnings Call

  • Basf SE's Dividend Analysis

    Basf SE(BASFY) recently announced a dividend of $0.92 per share, payable on 2024-05-10, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Basf SE's dividend performance and assess its sustainability.

  • Why Race Across The World couldn’t go through China

    Why wasn't Race Across The World able to go through China?

  • Bank of Montreal's Dividend Analysis

    Bank of Montreal (NYSE:BMO) recently announced a dividend of $1.51 per share, payable on 2024-05-28, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Bank of Montreal's dividend performance and assess its sustainability.

  • West Pharma posts beat-and-raise quarter aided by strong demand for injectables

    West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to manufacture injectable therapies. The company expects sales growth to ramp up as the year progresses, partly due to a surge in demand for components used in the packaging of newer treatments, including Novo Nordisk's diabetes drug Ozempic, weight-loss drug Wegovy, and Eli Lilly's diabetes drug Mounjaro. CEO Eric Green said that he expects a majority of sales growth to take place in the second half, as biotech clients work through their existing inventory.

  • Petroleo Brasileiro SA Petrobras's Dividend Analysis

    Petroleo Brasileiro SA Petrobras (NYSE:PBR) recently announced a dividend of $0.42 per share, payable on an unconfirmed future date, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Petroleo Brasileiro SA Petrobras's dividend performance and assess its sustainability.

  • Bristol Myers posts quarterly loss, revenue rises 5%

    Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue. The New Jersey-based drugmaker posted a loss of $4.40 per share, including charges for acquired research and development. On a net basis, Bristol's loss was $5.89 per share.

  • Munchener Ruckversicherungs-Gesellschaft AG's Dividend Analysis

    Munchener Ruckversicherungs-Gesellschaft AG (MURGY) recently announced a dividend of $1.61 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Munchener Ruckversicherungs-Gesellschaft AG's dividend performance and assess its sustainability.

  • Blackstone Inc's Dividend Analysis

    Blackstone Inc (NYSE:BX) recently announced a dividend of $0.83 per share, payable on 2024-05-06, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Blackstone Inc's dividend performance and assess its sustainability.